Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Monday, AnalystRatings.com reports. They currently have a $30.00 price objective on the stock. HC Wainwright’s price objective points to a potential upside of 3.52% from the company’s current price.
A number of other analysts also recently issued reports on STOK. JPMorgan Chase & Co. decreased their price objective on shares of Stoke Therapeutics from $34.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, December 3rd. BTIG Research started coverage on shares of Stoke Therapeutics in a research note on Tuesday, November 12th. They issued a “buy” rating and a $46.00 target price on the stock. Cowen reiterated a “buy” rating on shares of Stoke Therapeutics in a research note on Thursday, August 15th. Finally, Zacks Investment Research raised shares of Stoke Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research report on Wednesday, October 16th. Seven analysts have rated the stock with a buy rating, Stoke Therapeutics presently has an average rating of “Buy” and an average price target of $35.17.
Shares of Stoke Therapeutics stock opened at $28.98 on Monday. Stoke Therapeutics has a 1 year low of $19.21 and a 1 year high of $39.04. The company’s fifty day simple moving average is $25.39.
In other Stoke Therapeutics news, major shareholder Rtw Investments, Lp sold 16,434 shares of the business’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $28.70, for a total value of $471,655.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders acquired 205,216 shares of company stock valued at $5,771,421 over the last three months.
Several institutional investors and hedge funds have recently bought and sold shares of STOK. Platinum Investment Management Ltd. bought a new stake in shares of Stoke Therapeutics in the second quarter valued at approximately $29,000. Strs Ohio purchased a new stake in shares of Stoke Therapeutics during the 3rd quarter valued at approximately $51,000. Victory Capital Management Inc. bought a new position in Stoke Therapeutics in the 2nd quarter worth approximately $73,000. Ladenburg Thalmann Financial Services Inc. bought a new position in Stoke Therapeutics in the 2nd quarter worth approximately $88,000. Finally, Morgan Stanley bought a new position in Stoke Therapeutics in the 2nd quarter worth approximately $104,000. Hedge funds and other institutional investors own 48.61% of the company’s stock.
About Stoke Therapeutics
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.
Recommended Story: The risks of owning bonds
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.